Regeneron Reports Data From Three Independent Cohorts Evaluating An Investigational Combination Of LAG-3 Inhibitor Fianlimab And PD-1 Inhibitor Libtayo
Portfolio Pulse from Benzinga Newsdesk
Regeneron reports positive early clinical trial results for the combination of LAG-3 inhibitor Fianlimab and PD-1 inhibitor Libtayo, showing clinically meaningful and durable results across multiple clinical settings. The data will be presented at the 2023 ASCO Annual Meeting.

May 25, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's investigational combination of Fianlimab and Libtayo demonstrated positive early clinical trial results, which may boost investor confidence in the company.
The positive early clinical trial results for Regeneron's Fianlimab and Libtayo combination indicate potential for the treatment's success in multiple clinical settings. This may lead to increased investor confidence in the company's pipeline and potential for future revenue growth, resulting in a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100